摘要
目的评估重叠乙型肝炎病毒(HBV)或人类免疫缺陷病毒(HIV)感染的丙型肝炎患者丙型肝炎病毒(RNA)病毒载量与单纯丙型肝炎患者的差异.方法选取2017至2020年间本院1292例行丙肝基因分型的慢性丙肝患者,以其中行HCV RNA及HBV和HIV检测的397例丙型肝炎患者为研究对象,应用罗氏Cobas TaqMan试剂,对HCV RNA进行测定,并用PCR-荧光探针法检测HCV基因分型.结果HCV基因型中1b型比例最高,3a型比例最低.HCV重叠HBV或HIV感染率分别为9.1%与6.3%,6a型重叠HBV感染发生率最高,3a型重叠HIV感染发生率最高.2a型未见重叠HBV或HIV感染病例.1b型未重叠HBV感染患者HCV RNA滴度显著高于重叠HBV感染患者(P<0.05).在1b型、6a型及3a型,未重叠HIV感染患者与重叠HIV感染患者,其HCV RNA的滴度差异无统计学意义(P>0.05).结论重叠HBV感染的1b型患者HCV RNA滴度会降低;重叠HIV感染的患者,HCV RNA滴度无变化.
Objective To assess the difference in viral load of HCV RNA in patients with hepatitis C who overlap HBV or HIV infection and patients with hepatitis C alone.Methods A total of 1292 chronic hepatitis C patients with HCV genotyping in our hospital from 2017 to 2020 were selected,and 397 patients with hepatitis C who were tested for HCV RNA,HBV and HIV were selected as the research subjects.Roche Cobas TaqMan reagent was used to carry out the determination and detect the HCV genotyping by PCR-fluorescence probe method.Results Among HCV genotypes,the proportion of type 1 b is the highest,and the proportion of type 3 a is the lowest.HCV overlapping HBV or HIV infection rates were 9.1%and 6.3%,respectively.Type 6 a overlapping HBV infection had the highest incidence,and type 3 a overlapping HIV infection had the highest incidence.There was no overlapping HBV or HIV infection in type 2 a.The HCV RNA titer of patients with type 1 b non-overlapping HBV infection was significantly higher than that of patients with overlapping HBV infection(P<0.05).In type 1 b,type 6 a and type 3 a,there was no statistically significant difference in HCV RNA titer between patients with non-overlapping HIV infection and patients with overlapping HIV infection(P>0.05).Conclusions HCV genotype 1 b has a positive correlation with HCV RNA load for patients co-infection with HCV/HBV,and has not significant correlation with HCV RNA for patients co-infection with HCV/HIV.
作者
彭亚柏
朱秀云
刘赛云
王敏
龙寿斌
程文兵
蔡侃儒
刘甲野
PENG Yabai;ZHU Xiuyun;LIU Saiyun;WANG Min;LONG Shoubin;CHENG Wenbing;CAI Kanru;LIU Jiaye(Institute of Hepatology,Shenzhen Third People's Hospital,Shenzhen,Guangdong,China,518112)
出处
《分子诊断与治疗杂志》
2020年第7期861-863,886,共4页
Journal of Molecular Diagnostics and Therapy
基金
国家自然科学基金(81803299)。
